Imunon Ebitda vs Operating Income Analysis

IMNN Stock

USD 0.85 0.05 5.59%

Imunon financial indicator trend analysis is infinitely more than just investigating Imunon Inc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Imunon Inc is a good investment. Please check the relationship between Imunon Ebitda and its Operating Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Ebitda vs Operating Income

Ebitda vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Imunon Inc Ebitda account and Operating Income. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Imunon's Ebitda and Operating Income is 0.9. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Operating Income in the same time period over historical financial statements of Imunon Inc, assuming nothing else is changed. The correlation between historical values of Imunon's Ebitda and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Imunon Inc are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Ebitda i.e., Imunon's Ebitda and Operating Income go up and down completely randomly.

Correlation Coefficient

0.9

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ebitda

Operating Income

Operating Income is the amount of profit realized from Imunon Inc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Imunon Inc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Imunon's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Imunon Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 12th of December 2024, Selling General Administrative is likely to drop to about 6.2 M. In addition to that, Tax Provision is likely to drop to about (1.3 M)

	2021	2022	2023	2024 (projected)
Interest Expense	557K	4.6M	197.1M	206.9M
Depreciation And Amortization	702.9K	731.6K	720.0K	408.9K

Interest Expense Depreciation And Amortization

Imunon fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments
Total Assets		0.63	0.48	0.54	0.86	-0.04	0.32	-0.2	-0.29	0.1	0.52	0.57	0.54	0.8	0.03	-0.04	0.64	0.28	0.05	0.35	0.68	0.78	0.4	0.54	-0.5	0.65
Short Long Term Debt Total	0.63		0.35	0.41	0.32	-0.14	0.43	0.21	-0.21	-0.08	0.2	0.63	0.12	0.33	-0.22	-0.26	0.79	0.52	-0.11	0.2	0.75	0.3	0.62	0.44	-0.19	0.23
Other Current Liab	0.48	0.35		0.65	0.42	0.21	-0.38	0.09	-0.77	0.2	0.1	0.14	0.58	0.43	-0.08	0.51	0.18	0.42	0.6	0.76	0.31	0.48	0.15	0.49	-0.7	0.41
Total Current Liabilities	0.54	0.41	0.65		0.25	0.2	-0.17	0.04	-0.53	0.58	0.21	0.52	0.23	0.25	-0.35	0.15	0.5	0.08	0.26	0.51	0.68	0.27	0.67	0.56	-0.36	0.09
Total Stockholder Equity	0.86	0.32	0.42	0.25		0.0	0.11	-0.44	-0.23	-0.02	0.61	0.17	0.76	0.92	0.28	0.15	0.19	0.27	0.24	0.32	0.21	0.92	-0.08	0.21	-0.56	0.79
Property Plant And Equipment Net	-0.04	-0.14	0.21	0.2	0.0		-0.53	0.05	-0.6	0.01	0.05	-0.23	0.02	0.02	-0.02	0.69	-0.27	0.17	0.55	0.61	-0.08	0.07	-0.21	0.06	-0.38	0.0
Current Deferred Revenue	0.32	0.43	-0.38	-0.17	0.11	-0.53		0.11	0.52	-0.21	0.03	0.62	-0.18	0.02	-0.05	-0.81	0.65	0.01	-0.65	-0.52	0.44	-0.05	0.35	0.21	0.45	-0.01
Net Debt	-0.2	0.21	0.09	0.04	-0.44	0.05	0.11		0.03	-0.38	-0.84	0.22	-0.23	-0.42	-0.11	-0.04	0.26	-0.15	-0.2	-0.07	0.25	-0.42	0.28	0.42	-0.08	-0.02
Retained Earnings	-0.29	-0.21	-0.77	-0.53	-0.23	-0.6	0.52	0.03		-0.21	-0.16	-0.11	-0.35	-0.17	0.39	-0.78	-0.03	-0.62	-0.74	-0.99	-0.22	-0.23	-0.06	-0.37	0.68	-0.07
Accounts Payable	0.1	-0.08	0.2	0.58	-0.02	0.01	-0.21	-0.38	-0.21		0.32	0.12	-0.04	0.05	-0.32	-0.04	0.12	-0.1	-0.03	0.18	0.24	0.05	0.27	0.06	0.0	-0.23
Cash	0.52	0.2	0.1	0.21	0.61	0.05	0.03	-0.84	-0.16	0.32		0.02	0.37	0.63	0.07	0.0	0.1	0.32	0.28	0.21	0.12	0.63	-0.02	-0.26	-0.01	0.16
Non Current Assets Total	0.57	0.63	0.14	0.52	0.17	-0.23	0.62	0.22	-0.11	0.12	0.02		0.0	-0.03	-0.57	-0.34	0.86	0.23	-0.27	0.1	0.85	-0.06	0.81	0.59	0.02	-0.1
Non Currrent Assets Other	0.54	0.12	0.58	0.23	0.76	0.02	-0.18	-0.23	-0.35	-0.04	0.37	0.0		0.63	0.08	0.4	-0.1	0.28	0.51	0.4	-0.05	0.67	-0.21	-0.05	-0.53	0.58
Cash And Short Term Investments	0.8	0.33	0.43	0.25	0.92	0.02	0.02	-0.42	-0.17	0.05	0.63	-0.03	0.63		0.5	0.07	0.18	0.13	0.16	0.25	0.2	1.0	-0.1	0.2	-0.54	0.86
Net Receivables	0.03	-0.22	-0.08	-0.35	0.28	-0.02	-0.05	-0.11	0.39	-0.32	0.07	-0.57	0.08	0.5		-0.12	-0.29	-0.43	-0.07	-0.34	-0.35	0.49	-0.5	-0.11	-0.04	0.63
Common Stock Shares Outstanding	-0.04	-0.26	0.51	0.15	0.15	0.69	-0.81	-0.04	-0.78	-0.04	0.0	-0.34	0.4	0.07	-0.12		-0.5	0.35	0.8	0.8	-0.3	0.15	-0.37	-0.01	-0.67	0.12
Non Current Liabilities Total	0.64	0.79	0.18	0.5	0.19	-0.27	0.65	0.26	-0.03	0.12	0.1	0.86	-0.1	0.18	-0.29	-0.5		0.14	-0.42	0.02	0.96	0.14	0.84	0.65	0.01	0.1
Inventory	0.28	0.52	0.42	0.08	0.27	0.17	0.01	-0.15	-0.62	-0.1	0.32	0.23	0.28	0.13	-0.43	0.35	0.14		0.47	0.61	0.14	0.16	-0.03	0.03	-0.31	-0.05
Other Current Assets	0.05	-0.11	0.6	0.26	0.24	0.55	-0.65	-0.2	-0.74	-0.03	0.28	-0.27	0.51	0.16	-0.07	0.8	-0.42	0.47		0.75	-0.25	0.24	-0.33	-0.12	-0.4	0.05
Other Stockholder Equity	0.35	0.2	0.76	0.51	0.32	0.61	-0.52	-0.07	-0.99	0.18	0.21	0.1	0.4	0.25	-0.34	0.8	0.02	0.61	0.75		0.22	0.31	0.03	0.37	-0.73	0.15
Total Liab	0.68	0.75	0.31	0.68	0.21	-0.08	0.44	0.25	-0.22	0.24	0.12	0.85	-0.05	0.2	-0.35	-0.3	0.96	0.14	-0.25	0.22		0.17	0.88	0.73	-0.15	0.11
Total Current Assets	0.78	0.3	0.48	0.27	0.92	0.07	-0.05	-0.42	-0.23	0.05	0.63	-0.06	0.67	1.0	0.49	0.15	0.14	0.16	0.24	0.31	0.17		-0.13	0.18	-0.58	0.86
Short Term Debt	0.4	0.62	0.15	0.67	-0.08	-0.21	0.35	0.28	-0.06	0.27	-0.02	0.81	-0.21	-0.1	-0.5	-0.37	0.84	-0.03	-0.33	0.03	0.88	-0.13		0.56	0.08	-0.18
Intangible Assets	0.54	0.44	0.49	0.56	0.21	0.06	0.21	0.42	-0.37	0.06	-0.26	0.59	-0.05	0.2	-0.11	-0.01	0.65	0.03	-0.12	0.37	0.73	0.18	0.56		-0.48	0.34
Common Stock	-0.5	-0.19	-0.7	-0.36	-0.56	-0.38	0.45	-0.08	0.68	0.0	-0.01	0.02	-0.53	-0.54	-0.04	-0.67	0.01	-0.31	-0.4	-0.73	-0.15	-0.58	0.08	-0.48		-0.67
Short Term Investments	0.65	0.23	0.41	0.09	0.79	0.0	-0.01	-0.02	-0.07	-0.23	0.16	-0.1	0.58	0.86	0.63	0.12	0.1	-0.05	0.05	0.15	0.11	0.86	-0.18	0.34	-0.67

Click cells to compare fundamentals

Imunon Account Relationship Matchups

Imunon fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	38.3M	37.5M	74.0M	44.0M	21.9M	28.8M
Short Long Term Debt Total	11.3M	6.2M	6.6M	6.3M	1.6M	1.5M
Other Current Liab	2.3M	2.5M	3.2M	4.8M	3.4M	1.7M
Total Current Liabilities	7.9M	6.8M	6.8M	10.0M	7.4M	5.4M
Total Stockholder Equity	14.6M	18.6M	55.8M	29.3M	13.4M	15.9M
Property Plant And Equipment Net	1.8M	1.3M	1.4M	754K	2.3M	2.5M
Net Debt	4.5M	(11.0M)	(13.0M)	(5.2M)	(4.2M)	(4.4M)
Retained Earnings	(290.5M)	(312.0M)	(332.8M)	(368.7M)	(388.2M)	(368.8M)
Accounts Payable	2.9M	2.2M	2.5M	3.6M	3.5M	2.4M
Cash	6.9M	17.2M	19.6M	11.5M	5.8M	7.9M
Non Current Assets Total	22.0M	18.7M	22.1M	6.8M	3.7M	3.5M
Non Currrent Assets Other	333.3K	58.8K	6M	4.5M	50K	47.5K
Cash And Short Term Investments	14.9M	17.2M	49.5M	32.9M	15.7M	16.5M
Net Receivables	68.3K	21.4K	108.8K	128.9K	116.0K	110.2K
Common Stock Shares Outstanding	1.5M	2.1M	5.8M	7.1M	9.0M	9.5M
Liabilities And Stockholders Equity	38.3M	37.5M	74.0M	44.0M	21.9M	28.8M
Non Current Liabilities Total	15.8M	12.2M	11.5M	4.6M	1.1M	1.1M
Other Current Assets	1.4M	3.3M	2.4M	4.0M	2.5M	2.7M
Other Stockholder Equity	304.8M	330.2M	388.5M	397.9M	401.4M	421.5M
Total Liab	23.7M	18.9M	18.3M	14.6M	8.5M	12.8M
Total Current Assets	16.2M	18.8M	51.9M	37.2M	18.2M	19.2M
Accumulated Other Comprehensive Income	42.8K	0.0	(8K)	27K	60.8K	63.8K
Intangible Assets	16.3M	16.1M	13.5M	13.4M	15.4M	16.1M
Common Stock	232.6K	407.0K	58K	74K	94.0K	89.3K
Short Term Investments	8.0M	0.0	29.9M	21.4M	9.9M	12.7M
Net Tangible Assets	(3.5M)	3.2M	42.4M	29.3M	33.7M	35.4M
Other Assets	2.2M	1.9M	7.6M	6.1M	1.0	0.95
Long Term Debt	8.0M	3.9M	5.9M	4.6M	4.1M	5.1M
Net Invested Capital	24.4M	23.7M	61.7M	35.4M	13.4M	25.2M
Capital Stock	232.6K	407.0K	57.7K	74K	94.0K	140.5K
Net Working Capital	8.3M	12.1M	45.2M	27.1M	10.8M	10.3M
Property Plant Equipment	1.8M	1.3M	1.2M	704.2K	809.8K	1.2M

Pair Trading with Imunon

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.

Moving together with Imunon Stock

0.79	VALN	Valneva SE ADR	Pair Corr
0.69	ERNA	Eterna Therapeutics	Pair Corr

Moving against Imunon Stock

0.84	BMY	Bristol Myers Squibb	Pair Corr
0.75	GILD	Gilead Sciences	Pair Corr
0.61	ESPR	Esperion Therapeutics	Pair Corr
0.52	DYAI	Dyadic International	Pair Corr

The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.

The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Imunon Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Imunon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imunon Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imunon Inc Stock:

How To Invest In Imunon

Details

Is Imunon Stock a good investment?

Details

What is Imunon's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.91)

Revenue Per Share

0.014

Return On Assets

(0.67)

Return On Equity

(1.48)

The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Imunon Ebitda vs Operating Income Analysis

Ebitda vs Operating Income

Ebitda vs Operating Income Correlation Analysis

Correlation Coefficient

Ebitda

Operating Income

Imunon fundamental ratios Correlations

Imunon Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Imunon fundamental ratios Accounts

Pair Trading with Imunon

Moving together with Imunon Stock

Moving against Imunon Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.96	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.92	Total Stockholder Equity
Total Current Assets	+ 0.92	Total Stockholder Equity
Short Term Debt	+ 0.88	Total Liab
Total Stockholder Equity	+ 0.86	Total Assets

Other Stockholder Equity	- 0.99	Retained Earnings
Cash	- 0.84	Net Debt
Common Stock Shares Outstanding	- 0.81	Current Deferred Revenue
Common Stock Shares Outstanding	- 0.78	Retained Earnings
Retained Earnings	- 0.77	Other Current Liab
Other Current Assets	- 0.74	Retained Earnings